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InhibitorA group of cyclic imides was synthesized by reaction of amino-substituted benzenesulfonamides with a
series of acid anhydrides such as succinic, maleic, tetrahydrophthalic, pyrazine-2,3-dicarboxylic acid
anhydride, and substituted phthalic anhydrides. The synthesized sulfonamides were evaluated as car-
bonic anhydrase (CA, EC 4.2.1.1) inhibitors against the human (h) isoforms hCA I, II, IV and IX, involved
in a variety of diseases among which glaucoma, retinitis pigmentosa, etc. Some of these sulfonamides
showed effective inhibitory action (in the nanomolar range) against the cytosolic isoform hCA II and
the transmembrane, tumor-associated one hCA IX, making them interesting candidates for preclinical
evaluation in glaucoma or various tumors in which the two enzymes are involved. hCA I and IV were
on the other hand less inhibited by these sulfonamides, with inhibition constants in the micromolar
range.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
In previous works from these and other groups,1–11 the prepara-
tion and biological activity of cyclic imides incorporating primary
sulfonamide moieties were investigated. Phthalimides were defi-
nitely the privileged such scaffolds, being shown that they may
lead to effective inhibitors of the metallo-enzyme carbonic anhy-
drase (CA, EC 4.2.1.1).2,8–11 Furthermore, some substituted-phthal-
imides derived from aromatic sulfonamides such as sulfanilamide,
metanilamide or aminoalkyl-benzenesulfonamides, not only
showed low nanomolar activity as CA inhibitors (CAIs), but some
of them were also highly isoform-selective inhibitors for several
CAs involved in relevant pathologies such as glaucoma,12
epilepsy,13 obesity,14 or cancer.15 Indeed, of the 15 different
human(h) CA isoforms known to date, many are involved in such
and other pathologies,16 and finding isoform-selective inhibitorsis rather challenging, although many such compounds belonging
to various classes of inhibitors were reported by now to possess
such properties.17 Sulfonamides are in clinical use as CAIs for more
than 70 years, primarily as antiglaucoma agents or diuretics.12–17
Continuing our interest in sulfonamide CAIs, in this work we
report the synthesis and human (h) hCA I, II, IV and IX inhibitory
activity of cyclic imides obtained from amino-substituted benzene-
sulfonamides and a series of acid anhydrides such as succinic,
maleic, tetrahydrophthalic, pyrazine-2,3-dicarboxylic acid anhy-
dride, and substituted phthalic anhydrides.
2. Results and discussion
2.1. Drug design and chemistry
The leadmolecules for designing the CAIs synthesized here were
the sulfanilamides incorporating phthalimides moieties reported
earlier by one of these groups.2,9–11 We have shown that reaction
of amino-substituted benzenesulfonamides, such as sulfanilamide,
4-aminomethylbenzenesulfonamide or 4-aminoethylbenzenesul-
fonamide with phthalic anhydride or substituted-phthalic anhy-
drides leads to the corresponding phthalimides derivatives in
2 A.A.-M. Abdel-Aziz et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxxhigh yields.2,9–11 Furthermore, the new sulfonamides showed
effective inhibitory action against human CA isoforms I, II, IV and
IX.2,9–11
In the present work we have included diverse anhydrides for
the preparation of the imides, among which succinic, maleic,
tetrahydrophthalic, pyrazine-2,3-dicarboxylic acid anhydride, sub-
stituted phthalic anhydrides and norbornene dicarboxylic anhy-
dride. In this way, a wider range of chemical space is being
explored in order to investigate the effects of the cyclic imide scaf-
fold on the biological activity of these new sulfonamides.
The preparation of designed imides analogues 1–15 is shown in
Schemes 1 and 2. Condensation of acid anhydrides with 4-(2-ami-
noethyl)benzenesulfonamide in refluxing acetic acid afforded imi-
des 1–12 in good yields (Scheme 1).1–6
The remaining compounds, 13–15 (Scheme 2) were prepared in
a similar manner, but in this case the norbornene dicarboxylic
anhydride has been employed, leading to the tricyclic sulfon-
amides 13–15. Such scaffolds were not employed earlier for
obtaining CAIs.
Compounds 1–15 have been characterized in detail by physico-
chemical methods which confirmed their structures (see Experi-
mental for details).
2.2. Carbonic anhydrase inhibition
The newly synthesized compounds 1–15 were screened for
their CA inhibitory activity by a stopped-flow CO2 hydrase assay18
against the following isoforms: hCA I, II (cytosolic isoforms
involved in glaucoma13 and possibly other pathologic states)19
and hCA IV (an isoform involved in glaucoma and other eyeO
O
O
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O
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Scheme 1. Synthesis of the designed
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brane, tumor-associated hCA IX15,21 see Table 1.
The following structure–activity relationships (SARs) are
observed and reported for these series of compounds:
(i) The slow cytosolic isoform hCA I was inhibited by all the
investigated compounds with inhibition constants ranging
between 49.2 and 5121 nM. Sulfonamides incorporating
tetrahydrophthalimido and tert-butyl phthalimido moieties
3 and 7 showed the best inhibitory activity (KI of 49.2 and
95.7 nM, respectively). The other scaffolds were less potent
and inhibited this isoform in the high nanomolar range (KI
ranging between 179 and 865 nM). An interesting case was
constituted by the isosteric substitution of the chlorine
atoms in the phthalimido compounds 9 with bromine, in
10, which led to a significant decrease of the inhibitory
potency. Considering the monocyclic imides 1, 2 and the
bicyclic scaffold 3–15, the inhibition potency against the
hCA I did not vary significantly, except for compound 3,
which was the best inhibitor in the subseries. The linker
between the hexachloronorbornene dicarboxylic scaffold
and the sulfonamide part of the molecules present in 13,
14 and 15 also modulated the inhibition profile. The intro-
duction of a methylene chain, as in 14, increased the inhibi-
tion potency from 390 nM (13) to 201 nM (14), but a further
chain elongation, as in 15, decreased two times the KI for the
last compound.
(ii) hCA II, the dominant physiologic isoform, was inhibited by
all compounds in the low to high nanomolar range, with
KIs of 5–693 nM. The tetrahydrophthalimido derivative 3N
O
O
R= 5; H, 6; 5-Me, 7; 5-tert-But, 8; 5,6-Dichloro,
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Scheme 2. Synthesis of the designed hexachloro norbornene dicarboxylic imides derivatives 13–15.
Table 1
In vitro CA I, II, IV and IX inhibition with compounds 1–15 and acetazolamide as standard, by a stopped-flow, CO2 hydrase assay.18
Compound KI (nM)a
hCA I hCA II hCA IV hCA IX
1 446 73.6 9578 296
2 617 84.5 4849 274
3 49.2 5.0 973 296
4 441 426 9380 4188
5 491 49.4 5461 296
6 425 60.5 2925 390
7 95.7 89.9 9391 459
8 435 79.0 9358 428
9 562 68.1 9232 284
10 5121 693 8839 2389
11 865 140 8175 1636
12 179 85.4 8517 2667
13 390 41.5 83.0 13.7
14 201 54.6 912 16.9
15 484 23.2 6764 113.6
AAZ 250 12.1 74 25.2
a Mean from 3 different assays, by a stopped flow technique (errors were in the range of ±5–10% of the reported values).
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with a KI of 5 nM. The replacement of the monocyclic imido
scaffold with a bicyclic one did not have a significant effect
on the inhibition profiles of these sulfonamides (Table 1).
Only in the case of the pyrazine containing sulfonamide 4,
a decreased inhibitory potency was observed compared to
the other members of the series, this compound being one
of the weakest hCA II inhibitor (KI of 426 nM). The substitu-
tion on the phthalimido scaffold in compounds 5–12 did not
lead to significant changes in the inhibition potency, except
for the tetrabromo-substituted compound 10, which was a
medium potency – weak hCA II inhibitor (KI 693 nM). Fur-
thermore, the substitution of the nitro group from position
5 of compound 11 to position 4 (12), increased nearly twoPlease cite this article in press as: Abdel-Aziz A.-A.M., et al. Bioorg. Med. Chemtimes the potency of the corresponding sulfonamide against
this. Unlike the other cytosolic isoform, the introduction of a
linker in the norborneneimido derivatives 13–15 had diverse
effects on the inhibition profile: a decrease of the potency
was observed for a methylene linker (13, a KI of 41.5 nM
whereas 14 had a KI of 54.6 nM), whereas a further chain
elongation, as in 15, led to an increase of the potency with
a KI of 23.2 nM for the last compound.
(iii) The membrane-bound hCA IV was inhibited by most of com-
pounds investigated here in the micromolar range. The
monocyclic imido derivatives 1 and 2 showed KIs in the
range of 4.85–9.57 lM. The maleimido scaffold present in
3 led to a compound which was two times more potent than
the succinimido analog 1. Also for this isoform, the groups. (2017), http://dx.doi.org/10.1016/j.bmc.2017.01.032
4 A.A.-M. Abdel-Aziz et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxxpresent on the phthalimido scaffold did not influence signif-
icantly the inhibition profile. The compounds incorporating
hexachloronorbornene dicarboxylic scaffolds, 13–15,
showed a very interesting inhibition profile. The linker
between the imido scaffold and the sulfonamide head was
crucial for the inhibition potency. A direct correlation
between the length of the linker and the inhibition constant
was observed: 13 showed a nanomolar inhibition constant
(KI 83 nM), whereas an increase in the linker length to a
methylene or an ethylene group led to a drastic decrease
of potency, to the micromolar range (KI of 912 nM for com-
pound 14 and KI of 6764 nM for 15).
(iv) hCA IX, the tumor-associated isoform, was effectively inhib-
ited by many of the compounds reported here, in high
nanomolar range except for compounds 13 and 14 which
were active in the low nanomolar range. The monocyclic
imido derivatives 1 and 2 had nearly the same inhibition
profile with a KI of 296 nM and 274 nM, respectively. The
phthalimido scaffold present in 5–12 led to high nanomolar
hCA IX inhibitors, except for nitro-substituted compounds
11 and 12. For these compounds the potency has decreased
to the micromolar range, with KI of 1636 nM and 2667 nM,
respectively. Moreover, the hexachloro-norbornene scaffold
present in 13–15, led to an interesting SAR for the inhibition
of this isoform. Compounds 13 and 14 incorporating no lin-
ker or a methylene linker, exhibited low nanomolar KIs
whereas the derivative with a longer chain 15, as for isoform
hCA IV, led to a marked decreased in the inhibition potency
(Table 1).
3. Conclusions
We investigated a series of cyclic imides as CA inhibitors, con-
tinuing our research in this field of enzyme modulators. The com-
pounds were synthesized by reaction of amino-substituted
benzenesulfonamides with a series of dicarboxylic acid anhydrides
such as succinic, maleic, tetrahydrophthalic, pyrazine-2,3-dicar-
boxylic acid anhydride, as well as substituted phthalic anhydrides.
The synthesized sulfonamides were evaluated for the inhibition of
isoforms hCA I, II, IV and IX, involved in a variety of diseases among
which glaucoma, retinitis pigmentosa, tumors, etc. They showed
effective inhibitory action against the cytosolic isoform hCA II
and the transmembrane, tumor-associated one hCA IX, making
them interesting candidates for preclinical evaluation in glaucoma
or various tumors in which the two enzymes are involved. hCA I
and IV were on the other hand less inhibited by these
sulfonamides.4. Experimental part
4.1. Chemistry
Melting points (uncorrected) were recorded on Barnstead 9100
Electrothermal melting apparatus. IR spectra were recorded on a
FT-IR Perkin-Elmer spectrometer. 1H NMR and 13C NMR were
recorded in DMSO-d6 on Bruker 500 and 125 MHz instrument,
respectively, using TMS as internal standard (chemical shifts in d
ppm). Mass spectra were recorded on a Agilent 6320 Ion Trap mass
spectrometers. Elemental analysis was carried out for C, H and N at
the Research Centre of College of Pharmacy, King Saud University
and the results are within ±0.4% of the theoretical values. Com-
pounds 2, 5, 9, 10 and 11were prepared according to their reported
procedure.7–11Please cite this article in press as: Abdel-Aziz A.-A.M., et al. Bioorg. Med. Chem4.1.1. General procedure for the synthesis of cyclic imides 1, 3, 4, 6–8,
12
A mixture of 4-(2-aminoethyl)benzenesulfonamide (0.5 g,
2.5 mmol), anhydrous sodium acetate (0.41 g, 5.0 mmol) and an
acid anhydride (2.5 mmol) was stirred in glacial acetic acid
(15 mL). The mixture was heated under reflux for 12 h and the
reaction was monitored with the help of TLC. After completion of
reaction the solvent was removed under reduced pressure and
the crude solid obtained was washed with water, dried and re-
crystallised from an appropriate solvent.4.1.1.1. 4-(2-(2,5-Dioxopyrrolidin-1-yl)ethyl)benzenesulfonamide (1).
N
O
O
S
O
H2N
O
White crystals, M.p. 243–245, 95% yield (CH3OH); IR (KBr,
cm1) m: 3496 (NH), 1795, 1725 (C@O), 1382, 1194 (O@S@O); 1H
NMR (500 MHz, CDCl3/DMSO-d6): d 2.60 (s, 4H), 2.85–2.88 (t, 2H,
J = 7.5 Hz), 3.60–3.63 (t, 2H, J = 7.5 Hz), 7.28 (s, 1H), 7.35–7.37 (d,
2H, J = 8.0 Hz), 7.74–7.76 (d, 2H, J = 8.0 Hz), 8.22–8.23 (t, 1H,
J = 1.5 Hz); 13C NMR (125 MHz, CDCl3/DMSO-d6): d 28.37, 33.15,
39.21, 126.28, 129.47, 142.76, 142.78, 177.74; C12H14N2O4S: m/z
(281.99).4.1.1.2. 4-(2-(1,3-Dioxo-1,3,3a,4,7,7a-hexahydro-2H-isoindol-2-yl)
ethyl)benzenesulfonamide (3).
N
O
O
S
O
H2N
O
White crystals, M.p. 196–198, 91% yield (CH3OH); IR (KBr,
cm1) m: 3230 (NH), 1767, 1699 (C@O), 1333, 1179 (O@S@O); 1H
NMR (500 MHz, CDCl3/DMSO-d6): d 2.11–2.15 (m, 2H), 2.34–2.37
(d, 2H, J = 13.5 Hz), 2.83–2.86 (t, 2H, J = 7.5 Hz), 3.04–3.05 (t, 2H,
J = 3.0 Hz), 3.61–3.64 (t, 2H, J = 7.0 Hz), 5.73–5.77 (m, 2H), 7.21 (s,
2H), 7.27–7.29 (d, 2H, J = 8.0 Hz), 7.72–7.74 (d, 2H, J = 8.5 Hz); 13C
NMR (125 MHz, CDCl3/DMSO-d6): d 25.33, 33.09, 38.86, 42.74,
127.08, 129.33, 142.30, 142.42, 142.78, 179.94; C16H18N2O4S: m/z
(333.70).4.1.1.3. 4-(2-(5,7-Dioxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyrazin-6-yl)
ethyl)benzenesulfonamide (4).
N
O
O
S
O
H2N
O
N
N
Gray powder, M.p. 120–122, 76% yield (CH3OH/CH2Cl2); IR
(KBr, cm1) m: 3430 (NH), 1782, 1707 (C@O), 1318, 1129 (O@S@O);
1H NMR (500 MHz, DMSO-d6): d 2.76–2.79 (t, 2H, J = 7.0 Hz), 3.27–
3.03 (t, 2H, J = 7.0 Hz), 7.38–7.41 (t, 3H, J = 8.0 Hz), 7.74–7.75 (d,
3H, J = 8.5 Hz), 8.01–8.03 (t, 1H, J = 5.0 Hz), 9.11 (s, 1H); 13C NMR
(125 MHz, DMSO-d6): d 35.28, 38.65, 126.13, 129.54, 142.47,
144.22, 149.01, 169.77; C14H12N4O4S: m/z (331.76).. (2017), http://dx.doi.org/10.1016/j.bmc.2017.01.032
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amide (6).
N
O
O
S
O
H2N
O
White crystals, Mp 221–222, 93% yield (CH3OH/CH2Cl2); IR
(KBr, cm1) m: 3466 (NH), 1767, 1722 (C@O), 1300, 1131 (O@S@O);
1H NMR (500 MHz, CDCl3/DMSO-d6): d 2.43–2.45 (d, 3H, J = 9.0 Hz),
2.96–2.99 (t, 2H, J = 7.0 Hz), 3.79–3.84 (q, 2H, J = 8.0, 7.0 Hz), 6.97
(s, 2H), 7.26–7.00 (t, 2H, J = 8.5 Hz), 7.46–7.49 (t, 1H, J = 7.5 Hz),
7.53–7.54 (d, 1H, J = 7.5 Hz), 7.60–7.63 (t, 1H, J = 7.5 Hz), 7.71–
7.74 (t, 2H, J = 7.5 Hz); 13C NMR (125 MHz, CDCl3/DMSO-d6): d
22.00, 34.19, 38.62, 123.17, 123.80, 126.30, 129.19, 132.20,
134.76, 142.41, 142.50, 145.43, 167.91, 168.02; C17H16N2O4S: m/z
(344.07).
4.1.1.5. 4-(2-(5-(tert-Butyl)-1,3-dioxoisoindolin-2-yl)ethyl)benzene-
sulfonamide (7).
N
O
O
S
O
H2N
O
White powder, M.p. 160–162, 89% yield (CH3OH/CH2Cl2); IR
(KBr, cm1) m: 3493, 3095 (NH), 1780, 1727 (C@O), 1360, 1236
(O@S@O); 1H NMR (500 MHz, DMSO-d6): d 1.32 (s, 9H), 2.96–
2.99 (t, 2H, J = 7.0 Hz), 3.82–3.85 (t, 2H, J = 7.5 Hz), 6.94 (s, 2H),
7.28–7.30 (d, 2H, J = 8.0 Hz), 7.69–7.70 (t, 2H, J = 7.0 Hz), 7.73–
7.55 (t, 3H, J = 8.5 Hz); 13C NMR (125 MHz, DMSO-d6): d 31.17,
34.22, 35.73, 38.61, 120.30, 123.13, 126.32, 129.18, 131.22,
132.07, 142.39, 142.46, 158.56, 167.88, 168.26; C20H22N2O4S: m/z
(387.15).
4.1.1.6. 4-(2-(5,6-Dichloro-1,3-dioxoisoindolin-2-yl)ethyl)benzenesul-
fonamide (8).
N
O
O
S
O
H2N
O
Cl
Cl
White crystals, Mp 295–296, 91% yield (CH3OH); IR (KBr, cm1)
m: 3469, 3369 (NH), 1727, 1670 (C@O), 1366, 1167 (O@S@O); 1H
NMR (500 MHz, DMSO-d6): d 2.99–3.02 (t, 2H, J = 7.5 Hz), 3.83–
3.86 (t, 2H, J = 7.5 Hz), 7.31 (s, 2H), 7.40–7.42 (d, 2H, J = 8.0 Hz),
7.71–7.73 (t, 2H, J = 8.5 Hz), 8.15–8.16 (t, 2H, J = 8.5 Hz); 13C NMR
(125 MHz, DMSO-d6): d 33.78, 39.34, 125.74, 126.26, 129.67,
131.88, 137.81, 142.80, 166.32; C16H12Cl2N2O4S: m/z (398.60).
4.1.1.7. 4-(2-(4-Nitro-1,3-dioxoisoindolin-2-yl)ethyl)benzenesulfon-
amide (12).
N
O
O
S
O
H2N
O
NO2Please cite this article in press as: Abdel-Aziz A.-A.M., et al. Bioorg. Med. ChemYellow powder, Mp 238–240, 86% yield (CH3OH/CH2Cl2); IR
(KBr, cm1) m: 3485 (NH), 1779, 1732 (C@O), 1362, 1228 (O@S@O);
1H NMR (500 MHz, DMSO-d6): d 2.99–3.02 (t, 2H, J = 6.0 Hz), 3.83–
3.86 (t, 2H, J = 7.5 Hz), 7.32 (s, 2H), 7.44–7.45 (d, 2H, J = 8.5 Hz),
7.73–7.75 (t, 2H, J = 6.0 Hz), 8.05–8.07 (t, 1H, J = 5.0 Hz), 8.15–
8.16 (t, 1H, J = 5.5 Hz), 8.28–8.29 (t, 1H, J = 5.0 Hz); 13C NMR
(125 MHz, DMSO-d6): d 33.72, 39.44, 123.44, 126.29, 127.32,
128.80, 129.65, 133.92, 136.70, 142.82, 142.89, 144.76, 163.65,
166.19; C16H13N3O6S: m/z (374.54).
4.1.2. General procedure for the synthesis of cyclic imides 13–15
A mixture of benzenesulfonamide (2.5 mmol), anhydrous
sodium acetate (0.41 g, 5.0 mmol) and 4,5,6,7,8,8-hexachloro-
3a,4,7,7a-tetrahydro-4,7-methanoisobenzofuran-1,3-dione
(0.927 g, 2.5 mmol) were stirred in glacial acetic acid (15 mL) and
heated under reflux for 6 h. After the evaporation of the solvent
under reduced pressure, the precipitate obtained was washed with
water, dried and re-crystallised from an appropriate solvent.
4.1.2.1. 4-(4,5,6,7,8,8-Hexachloro-1,3-dioxo-1,3,3a,4,7,7a-hexahydro-
2H-4,7-methanoisoindol-2-yl)benzenesulfonamide (13).
N
O
O
Cl
Cl
Cl
Cl
Cl
Cl
S
O
NH2
O
White powder, M.p. > 350, 95% yield (CH3OH); IR (KBr, cm1) m:
3370, 3250 (NH), 1769, 1708 (C@O), 1388, 1144 (O@S@O); 1H NMR
(500 MHz, DMSO-d6): d 4.28 (s, 2H), 7.34–7.35 (d, 2H, J = 8.5 Hz),
7.52 (s, 2H), 8.00–8.01 (d, 2H, J = 8.5 Hz); 13C NMR (125 MHz,
DMSO-d6): d 52.70, 79.44, 104.15, 127.52, 131.12, 134.07, 145.07,
169.85; C15H8Cl6N2O4S: m/z (526.43).
4.1.2.2. 4-((4,5,6,7,8,8-Hexachloro-1,3-dioxo-1,3,3a,4,7,7a-hexahy-
dro-2H-4,7-methanoisoindol-2-yl)methyl)benzenesulfonamide (14).
S
O NH2
O
N
O
O
Cl
Cl
Cl
Cl
Cl
Cl
White powder, M.p. 201–203, 87% yield (CH3OH/CH2Cl2); IR
(KBr, cm1) m: 3307, 3229 (NH), 1759, 1711 (C@O), 1369, 1180
(O@S@O); 1H NMR (500 MHz, CDCl3/DMSO-d6): d 3.95 (s, 2H),
4.52 (s, 2H), 6.89 (s, 2H), 7.36–7.38 (d, 2H, J = 8.5 Hz), 7.77–7.78
(d, 2H, J = 8.0 Hz); 13C NMR (125 MHz, CDCl3/DMSO-d6): d 42.49,
52.09, 79.43, 104.37, 126.39, 129.74, 130.58, 138.23, 143.87,
170.05; C16H10Cl6N2O4S: m/z (539.50).
4.1.2.3. 4-(2-(4,5,6,7,8,8-Hexachloro-1,3-dioxo-1,3,3a,4,7,7a-hexahy-
dro-2H-4,7-methanoisoindol-2-yl)ethyl)benzenesulfonamide (15).
S
O
NH2
O
N
O
O
Cl
Cl
Cl
Cl
Cl
Cl. (2017), http://dx.doi.org/10.1016/j.bmc.2017.01.032
6 A.A.-M. Abdel-Aziz et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxxWhite powder, M.p. 226–228, 83% yield (CH3OH/CH2Cl2); IR
(KBr, cm1) m: 3323, 3213 (NH), 1751, 1714 (C@O), 1373, 1165
(O@S@O); 1H NMR (500 MHz, CDCl3/DMSO-d6): d 2.71–2.74 (t,
2H, J = 10.0 Hz), 3.55–3.58 (q, 2H, J = 10.0, 5.5 Hz), 4.01–4.02 (d,
2H, J = 3.5 Hz), 7.17 (s, 2H), 7.33–7.34 (t, 2H, J = 4.0 Hz), 7.76–
7.78 (q, 2H, J = 8.5, 4.5 Hz); 13C NMR (125 MHz, CDCl3/DMSO-d6):
d 33.42, 39.60, 52.17, 79.26, 104.36, 126.41, 129.20, 130.71,
141.39, 143.04, 170.38; C17H12Cl6N2O4S: m/z (552.19).
4.2. Carbonic anhydrase inhibition
An SX.18MV-R Applied Photophysics (Oxford, UK) stopped-flow
instrument has been used to assay the catalytic/inhibition of vari-
ous CA isozymes.18 Phenol Red (at a concentration of 0.2 mM) has
been used as indicator, working at the absorbance maximum of
557 nm, with 10 mM Hepes (pH 7.4) as buffer, 0.1 M Na2SO4 or
NaClO4 (for maintaining constant the ionic strength; these anions
are not inhibitory in the used concentration),22 following the CA-
catalyzed CO2 hydration reaction for a period of 5–10 s. Saturated
CO2 solutions in water at 25 C were used as substrate. Stock solu-
tions of inhibitors were prepared at a concentration of 10 mM (in
DMSO-water 1:1, v/v) and dilutions up to 0.01 nM done with the
assay buffer mentioned above. At least 7 different inhibitor con-
centrations have been used for measuring the inhibition constant.
Inhibitor and enzyme solutions were preincubated together for
10 min at room temperature prior to assay, in order to allow for
the formation of the E-I complex. Triplicate experiments were done
for each inhibitor concentration, and the values reported through-
out the paper are the mean of such results. The inhibition constants
were obtained by non-linear least-squares methods using the
Cheng-Prusoff equation, as reported earlier,11 and represent the
mean from at least three different determinations. All CA isozymes
used here were recombinant proteins obtained as reported earlier
by our group.23–26
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